GLPwatch
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
J Fam Pract · 2010
Last updated 2026-09-22GLP-1 agonists and DPP-4 inhibitors have generally safe profiles with low risk of low blood sugar. These drugs may also help with weight loss and heart health, especially GLP-1 agonists, making them suitable options for the patients described in the study.
AI summary of the abstract below.
| Journal | J Fam Pract, 2010 |
|---|---|
| Citations | 9 |
| Relative citation ratio | 0.24 |
| NIH percentile | 15 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction |
Abstract
The overall safety profiles of GLP-1 agonists and DPP-4 inhibitors are favorable, with a low incidence of hypoglycemia. This attribute, along with their weight and cardiovascular benefits, particularly with the GLP-1 agonists, make them appropriate choices in our 3 patient cases. Ongoing safety investigations with GLP-1 agonists and DPP-4 inhibitors will provide further clarity to the complete safety profiles of these agents.
Verbatim abstract via PubMed 20824236 ↗